Feb 1, 2024 | Business
Eisai Co., Ltd. announced today that fully-fledged operations have begun at Eisai Pharmaceuticals Africa (Pty) Ltd (“Eisai South Africa”), a pharmaceutical sales subsidiary recently established in Johannesburg, South Africa, and direct sales operations and business activities have commenced in Africa. Eisai South Africa is a wholly-owned subsidiary of Eisai.
South Africa has a population of about 60 million, with the largest pharmaceutical market in Sub-Saharan Africa at 3.477 billion USD in 2022, exhibiting an average growth rate of 6% in local currency terms from 2018 to 2022.1 In 2017, Eisai started selling Eisai products in South Africa through local distribution partners, marketing anticancer drugs Halaven® and Lenvima®, and the antiepileptic drug Fycompa®. Eisai South Africa was established in May 2022, and took over the marketing authorization approvals for those products from the local distribution partners. Eisai South Africa has started sales and marketing activities directly for Lenvima and Fycompa from January 2024, as well as Halaven from February 2024. Additionally, the market launch of anti-insomnia drug Dayvigo® is planned for June 2024. Eisai South Africa plans to expand sales of these products to other Southern African Development Community (SADC) member states, such as Namibia, Botswana, Zambia, and Zimbabwe. Moreover, a regulatory filing for Alzheimer’s disease treatment LEQEMBI® in South Africa is scheduled in FY2023 ending March 31, 2024.
Kenya Branch, Eisai Pharmaceuticals Africa (Pty) Ltd (“Eisai Kenya”), established in October 2022 in Nairobi, Republic of Kenya, as a branch of Eisai South Africa, will expand access to new treatments such as Halaven and Fycompa in Kenya and other East African Community (EAC) countries, such as Tanzania and Uganda through local distribution partners. Eisai Kenya will also serve as a site for collaboration with research institutes, such as Drugs for Neglected Diseases initiative (DNDi), an important local partner in the global health field of Neglected Tropical Diseases (NTDs) and malaria, one of Eisai’s focus areas, and the Nagasaki University Institute of Tropical Medicine’s Kenya Research Station, to further expand networks of people and promote R&D and access to medicines.
With the rapid economic growth and improvement of the medical environment in Africa in recent years, the average life expectancy is increasing, and there is expected to be a growing demand for cancer and dementia treatments. Meanwhile, improving access to medicines for NTDs, which cause a vicious cycle of poverty and infectious diseases in endemic areas, potentially hindering economic growth, is also an imminent challenge. Seeking solutions to these challenges in Africa, Eisai will continue its initiatives to deliver necessary medicines to the patients who need them through Eisai South Africa and Eisai Kenya.
For more information, visit www.eisai.com/news/2024/news202409.html.
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Topic: Press release summary
Jan 19, 2023 | Business
Eisai Co., Ltd. announced today that fully-fledged operations and business activities have begun at Eisai Israel Ltd., a pharmaceutical sales subsidiary recently established in Tel Aviv in the State of Israel (Israel). Eisai Israel is a wholly-owned subsidiary of Eisai’s European regional headquarters, Eisai Europe Ltd.
Israel’s pharmaceutical market reached 5.3 billion USD in 2021.1 The compound annual growth rate of the Israel pharmaceutical market from 2018 to 2021 was +8.56%1 and the market is expected to continue to grow steadily, with a high penetration rate of innovative medicines.
In 2011, Eisai Europe started business in Israel marketing and selling Eisai products through local distribution partners, and mainly marketed Lenvima, Halaven, Fycompa and Inovelon. Eisai Israel was established in August 2021, and in January 2023, became the marketing authorization holder of the Eisai products in Israel. Eisai Israel will now perform sales and marketing activities for these products. The company plans to launch its other global brands in the future.
With the commencement of operations at Eisai Israel, Eisai aims to utilize its own drug sales system in Israel, deliver innovative new drugs to more patients in Israel as quickly as possible, and contribute to improving the benefits of patients and their families.
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Copyright ©2023 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Jun 8, 2022 | Business
Mitsubishi Heavy Industries, Ltd. (MHI), with support from its power solutions brand, Mitsubishi Power, has begun a feasibility study on the use of ammonia as fuel for power plants in Indonesia.
The two proposals to carry out this study were recently adopted by Japan’s Ministry of Economy, Trade and Industry (METI), to uncover and leverage the advanced technologies and expertise of Japanese companies to meet new global demands for infrastructure and contribute to global socioeconomic development. This is part of efforts to support energy decarbonization in the country through the Asia Energy Transition Initiative (AETI)(1).
These two studies will examine the feasibility of utilizing ammonia(2) at the Suralaya coal-fired power station and at an existing natural gas-fired power station in the country, derived from the abundant oil and natural gas produced in Indonesia, with the goal of establishing an integrated ammonia value chain encompassing production, transport, fuel consumption, and CO2 storage.
The two proposals selected by METI for its “Feasibility Studies for the Overseas Deployment of High-quality Energy Infrastructure (Projects to Survey the Promotion of Overseas Infrastructure Development by Japanese Corporations)” are the “Survey of the Feasibility of Ammonia Mixed Fuel Combustion at the Suralaya Power Station in Indonesia and Evaluation of the Overall Value Chain” (the “Suralaya Project”), and the “Survey of the Feasibility of Retrofitting an Existing Natural Gas-fired Power Station in Indonesia to Introduce Power Generation Using Ammonia and the Establishment of a Value Chain” at an existing natural gas-fired power station (the “Existing Natural Gas-fired Power Station Project”). Both proposals will examine the potential reduction of CO2 resulting from energy generation and its effects. The potential global impact, and high degree of utility and innovativeness of these feasibility studies, are regarded as significant to policies involving the Japanese government.
The main objective of the Suralaya Project is to calculate the economic efficiency of the envisioned process of transporting ammonia produced in Indonesia to the power station and consuming it as fuel for generating power. The project will be conducted jointly with Mitsubishi Corporation and Nippon Koei Co., Ltd., with operations expected to begin around 2030.
The main objective of the Existing Natural Gas-fired Power Station Project is to calculate the economic efficiency of transporting ammonia and hydrogen produced in Indonesia to a nearby existing natural gas-fired power station as a fuel to generate power. The project will be conducted jointly with Tokyo Electric Power Services Co., Ltd. (TEPSCO), with operations expected to begin in the second half of this decade.
Both projects will examine the effectiveness of CO2 reductions throughout the value chain, with MHI focusing primarily on the outcome of introducing ammonia power generation technologies. In addition, MHI plans to conduct a feasibility study based on institutional support measures such as financial support from the Japanese government, and decarbonization efforts and carbon pricing by Indonesia. Through the implementation of these projects, MHI hopes to contribute to the expansion of energy infrastructure exports from Japan.
Indonesia has announced a policy of deriving 23% of its power supply from renewable energy by 2025, and 28% by 2035. MHI and Mitsubishi Power will make a concerted effort as a corporate group, working in cooperation with Indonesia’s state-owned power company group and the Bandung Institute of Technology (ITB), to support approaches that help the country achieve its targets.
Going forward, with encouragement from METI’s adoption of these feasibility studies, MHI and Mitsubishi Power will contribute to further decarbonization in Indonesia, and provide momentum for the global deployment of the company’s net zero energy transition policy through the projects.
(1) The Asia Energy Transition Initiative (AETI) was announced by the Government of Japan in May 2021 and aims to promote carbon neutrality in Asia while simultaneously achieving sustainable economic growth.
(2) Blue hydrogen, which has no greenhouse effect, is obtained by splitting natural gas or similar material into hydrogen (H2) and carbon dioxide (CO2), either by steam methane reforming (SMR) or auto thermal reforming (ATR), with the CO2 captured and stored rather than released into the atmosphere. Combining this with nitrogen (N2) produces blue ammonia (NH3), which also has no greenhouse effect. Blue ammonia will be used in the two projects.
About MHI Group
Mitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com.
Copyright ©2022 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
